Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapablursen in Phlebotomy Dependent Polycythemia Vera
NCT05143957Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Dec 2021
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Gene Silencing, Small Interfering RNA (siRNA)
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of sapablursen in polycythemia vera (PV) (2 arms), sponsored by Ionis Pharmaceuticals. Primary endpoint: Change in the frequency of phlebotomy. Started Dec 2021; status: completed.
02
Drugs
sapablursen
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT05143957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05143957.